Genetic markers found by New York City researchers that could flag patients most at risk of erectile dysfunction after radiotherapy for prostate cancer may help doctors pick the best treatment for their patients.
A key official in France is keeping up pressure on Sanofi about its planned work force reductions in the country, sticking to the position that the drug giant ($SNY) hasn't done enough to protect jobs. And French Industry Minister Arnaud Montebourg makes clear in reports today that he isn't satisfied with how the company plans to secure the future of its R&D site in Toulouse.
Forget fast tracks and accelerated approvals. A group of distinguished scientists has mapped out a whole new approach to dramatically speed up drug development. And they say their clinical road map will allow the FDA to double the number of new drug approvals it makes each year.
Amid slumping cardiac device sales and industry-wide belt-tightening over the impending device tax, the potential payday for hypertension technologies stands out, to say the least. Check out the full report >>
Amid slumping cardiac device sales and industry-wide belt-tightening over the impending device tax, the potential payday for hypertension technologies stands out, to say the least. Click here to check out the full report >>
Merck's experimental lonafarnib failed to impress as an experimental treatment for cancer, yet a study of the drug in patients with an extremely rare and deadly condition called progeria has yielded some promising data.
While it is not mentioned in the announcement, the drug-resistant superbug that has now killed 7 people infected at the National Institutes of Health Clinical Center had to be on the mind of FDA officials when they decided to form a task force to help push antibacterial drug development.
Tiny bubbles of peptides could safely deliver drugs and genes around the body, according to research at Kansas State University, with potential to treat cancer and neurodegenerative diseases.
Seeking to break into the market for bleeding-disorder drugs, Biogen Idec and partner Swedish Orphan Biovitrium (Sobi) reported positive top-line data from a late-stage study of a long-lasting clotting factor treatment for patients with hemophilia B. With the key data in hand, Biogen said this morning that it plans to move forward with an application for approval of the treatment in the first half of 2013.
Mainstay Medical is developing a "pacemaker for the back" to treat chronic lower back pain, and the company now has $20 million in its coffers to fund the project thanks to an over-subscribed financing round.